Pathogenetics of the RASopathies
- PMID: 27412009
- PMCID: PMC6283265
- DOI: 10.1093/hmg/ddw191
Pathogenetics of the RASopathies
Abstract
The RASopathies are defined as a group of medical genetics syndromes that are caused by germ-line mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. Taken together, the RASopathies represent one of the most prevalent groups of malformation syndromes affecting greater than 1 in 1,000 individuals. The Ras/MAPK pathway has been well studied in the context of cancer as it plays essential roles in growth, differentiation, cell cycle, senescence and apoptosis, all of which are also critical to normal development. The consequence of germ-line dysregulation leads to phenotypic alterations of development. RASopathies can be caused by several pathogenetic mechanisms that ultimately impact or alter the normal function and regulation of the MAPK pathway. These pathogenetic mechanisms can include functional alteration of GTPases, Ras GTPase-activating proteins, Ras guanine exchange factors, kinases, scaffolding or adaptor proteins, ubiquitin ligases, phosphatases and pathway inhibitors. Although these mechanisms are diverse, the common underlying biochemical phenotype shared by all the RASopathies is Ras/MAPK pathway activation. This results in the overlapping phenotypic features among these syndromes.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
The RASopathies.Annu Rev Genomics Hum Genet. 2013;14:355-69. doi: 10.1146/annurev-genom-091212-153523. Epub 2013 Jul 15. Annu Rev Genomics Hum Genet. 2013. PMID: 23875798 Free PMC article. Review.
-
Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.Am J Med Genet A. 2018 Dec;176(12):2924-2929. doi: 10.1002/ajmg.a.40632. Epub 2018 Oct 10. Am J Med Genet A. 2018. PMID: 30302932 Free PMC article.
-
Molecular Genetics of Noonan Syndrome and RASopathies.Pediatr Endocrinol Rev. 2019 May;16(Suppl 2):435-446. doi: 10.17458/per.vol16.2019.lm.molecularnoonan. Pediatr Endocrinol Rev. 2019. PMID: 31115195 Review.
-
The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.Curr Opin Genet Dev. 2009 Jun;19(3):230-6. doi: 10.1016/j.gde.2009.04.001. Epub 2009 May 19. Curr Opin Genet Dev. 2009. PMID: 19467855 Free PMC article. Review.
-
RASopathies for Radiologists.Radiographics. 2024 May;44(5):e230153. doi: 10.1148/rg.230153. Radiographics. 2024. PMID: 38602868
Cited by
-
The RASopathies: from pathogenetics to therapeutics.Dis Model Mech. 2022 Feb 1;15(2):dmm049107. doi: 10.1242/dmm.049107. Epub 2022 Feb 18. Dis Model Mech. 2022. PMID: 35178568 Free PMC article. Review.
-
Comprehensive Genetic Analysis of RASopathy in the Era of Next-Generation Sequencing and Definition of a Novel Likely Pathogenic >KRAS Variation.Mol Syndromol. 2022 Feb;13(2):88-98. doi: 10.1159/000520722. Epub 2022 Jan 7. Mol Syndromol. 2022. PMID: 35418823 Free PMC article.
-
Update on Genetic Conditions Affecting the Skin and the Kidneys.Front Pediatr. 2018 Mar 2;6:43. doi: 10.3389/fped.2018.00043. eCollection 2018. Front Pediatr. 2018. PMID: 29552546 Free PMC article. Review.
-
MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model.Dis Model Mech. 2022 Feb 1;15(2):dmm049166. doi: 10.1242/dmm.049166. Epub 2021 Nov 19. Dis Model Mech. 2022. PMID: 34553752 Free PMC article.
-
RASopathy mutations provide functional insight into the BRAF cysteine-rich domain and reveal the importance of autoinhibition in BRAF regulation.Mol Cell. 2022 Nov 17;82(22):4262-4276.e5. doi: 10.1016/j.molcel.2022.10.016. Epub 2022 Nov 7. Mol Cell. 2022. PMID: 36347258 Free PMC article.
References
-
- Yoon S., Seger R. (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors, 24, 21–44. - PubMed
-
- Aoki Y., Niihori T., Kawame H., Kurosawa K., Ohashi H., Tanaka Y., Filocamo M., Kato K., Suzuki Y., Kure S., et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat. Genet., 37, 1038–1040. - PubMed
-
- Estep A.L., Tidyman W.E., Teitell M.A., Cotter P.D., Rauen K.A. (2006) HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am. J. Med. Genet. A, 140, 8–16. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical